HVB MINI FUTURE BEAR - ASTRAZENECA | Real-time BOERSE MUENCHEN 07:16:22 06/06/2024 pm IST | ||
| 2.18 EUR | -2.68% |
|
| Current month | -14.50% | ||
| 1 month | -18.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 06/24/06 | 2.18 | -2.68% |
| 05/24/05 | 2.24 | -5.49% |
| 04/24/04 | 2.37 | -3.66% |
| 03/24/03 | 2.46 | -6.11% |
| 31/24/31 | 2.62 | -7.42% |
Real-time BOERSE MUENCHEN
Last update June 06, 2024 at 07:16 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HC69S9 |
| ISIN | DE000HC69S98 |
| Date issued | 25/04/2023 |
| Strike | 14,432 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.73 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.95 € |
|---|---|
| Lowest since issue | 2.18 € |
| Spread | 0.01 € |
| Spread % | 0.46% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
172.9
USD
Spread / Average Target
+8.19%
- Stock Market
- Certificates
- Certificat
